Dermot Moynagh
About Dermot Moynagh
Dermot Moynagh is the Market Access Strategy Lead for Innovative Medicines at Bristol-Myers Squibb, with extensive experience in global market access and pricing strategies.
Company
Dermot Moynagh is currently employed at Bristol-Myers Squibb, working out of Lawrenceville, NJ. The company, known for its extensive pharmaceutical research and innovative medicines, is where Dermot leads Market Access Strategy for specific medical indications.
Title
Dermot holds the position of Market Access Strategy Lead for Innovative Medicines at Bristol-Myers Squibb. In this capacity, he is responsible for developing and executing strategies that ensure the accessibility and affordability of their medications.
Previous Experience at Pfizer
Dermot Moynagh served as Director of Global Market Access Strategy at Pfizer for multiple tenures— from 2016 to 2018, 2014 to 2016, and 2011 to 2014. Prior to these roles, he was the Associate Director for Global Pricing & Reimbursement Strategy at Pfizer from 2007 to 2011. His work involved developing cost-effectiveness models and budget impact calculators, conducting therapeutic area analyses, and managing international price referencing.
Previous Experience at Wyeth Pharmaceuticals
At Wyeth Pharmaceuticals, Dermot held several roles, including Project Manager at the Global Brand Team Project Management from 2005 to 2007 and Senior Analyst in Global Marketing Research from 2001 to 2004. His responsibilities included project management and market research analysis aimed at supporting global brand strategies.
Educational Background
Dermot studied Pharmaceutical Marketing at Saint Joseph's University Erivan K. Haub School of Business, earning an MBA between 2007 and 2010. He also holds an MSc in Chemistry from Trinity College, Dublin, completed between 1993 and 2005, and a BSc in Science from University College Dublin, achieved from 1989 to 1992.
Professional Expertise
Dermot has a deep-seated expertise in therapeutic area situation analyses, development of cost-effectiveness models, and evaluation of price change proposals. He has led advisory boards, HTA engagements, and designed payer-centric Phase 3 clinical trials in collaboration with R&D teams. His expertise also extends to international price referencing and tender strategy management.